Loading...

Bonesupport Holding AB (publ)

2B4.F•XETRA
Healthcare
Medical - Instruments & Supplies
€26.60
€-0.28(-1.04%)

Bonesupport Holding AB (publ) (2B4.F) Stock Overview

Explore Bonesupport Holding AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 76.0/100

Key Financials

Market Cap1.8B
P/E Ratio159.99
EPS (TTM)$0.17
ROE0.18%
Fundamental Analysis

AI Price Forecasts

1 Week$22.90
1 Month$25.27
3 Months$34.18
1 Year Target$53.56

2B4.F Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Bonesupport Holding AB (publ) (2B4.F) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 62.20, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $53.56.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 159.99 and a market capitalization of 1.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

62.20RSI (14)
0.45MACD
19.48ADX
Revenue Growth
52.05%
↑ 52.05%
Profit Growth
€1.86
↓ 45.41%
EPS Growth
€1.86
↓ 45.89%
Operating Margin
16.49%
↑ 1092.73%
ROE
17.73%
↓ 45.41%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 2B4.FAnalyst Recommendations details for 2B4.F are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.

CEO

Emil Billbäck

Employees

140

Headquarters

Scheelevägen 19, Lund

Founded

2017

Frequently Asked Questions

;